These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 26770398)

  • 21. Adaptation to chronic exposure to sepantronium bromide (YM155), a prototypical survivin suppressant is due to persistent DNA damage-response in breast cancer cells.
    Wani TH; Surendran S; Mishra VS; Chaturvedi J; Chowdhury G; Chakrabarty A
    Oncotarget; 2018 Sep; 9(71):33589-33600. PubMed ID: 30323901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. β-Elemene Enhances the Sensitivity of Osteosarcoma Cells to Doxorubicin via Downregulation of Peroxiredoxin-1.
    Zhang S; Guo W
    Onco Targets Ther; 2021; 14():3599-3609. PubMed ID: 34113126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effective combination therapy against human osteosarcoma: doxorubicin plus curcumin co-encapsulated lipid-coated polymeric nanoparticulate drug delivery system.
    Wang L; Wang W; Rui Z; Zhou D
    Drug Deliv; 2016 Nov; 23(9):3200-3208. PubMed ID: 26987435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. YM155 enhances docetaxel efficacy in ovarian cancer.
    Hou LJ; Huang XX; Xu LN; Zhang YY; Zhao N; Ou RY; Li WF; Zhang WJ; Jiang QW; Yang Y; Wei MN; Huang JR; Wang K; Yuan ML; Xing ZH; Shi Z; Yan XJ
    Am J Transl Res; 2018; 10(3):696-708. PubMed ID: 29636860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic Effects of AICAR and DOX Conjugated Multifunctional Nanoparticles in Sensitization and Elimination of Cancer Cells via Survivin Targeting.
    Daglioglu C; Okutucu B
    Pharm Res; 2017 Jan; 34(1):175-184. PubMed ID: 27783307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decrease in stathmin expression by arsenic trioxide inhibits the proliferation and invasion of osteosarcoma cells via the MAPK signal pathway.
    Feng T; Xu J; He P; Chen Y; Fang R; Shao X
    Oncol Lett; 2017 Aug; 14(2):1333-1340. PubMed ID: 28789348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting Survivin Enhances Chemosensitivity in Retinoblastoma Cells and Orthotopic Tumors.
    Ferrario A; Luna M; Rucker N; Wong S; Lederman A; Kim J; Gomer C
    PLoS One; 2016; 11(4):e0153011. PubMed ID: 27050416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Testing of the Survivin Suppressant YM155 in a Large Panel of Drug-Resistant Neuroblastoma Cell Lines.
    Michaelis M; Voges Y; Rothweiler F; Weipert F; Zia-Ahmad A; Cinatl J; von Deimling A; Westermann F; Rödel F; Wass MN; Cinatl J
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32131402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autophagy prevents doxorubicin‑induced apoptosis in osteosarcoma.
    Zhao D; Yuan H; Yi F; Meng C; Zhu Q
    Mol Med Rep; 2014 May; 9(5):1975-81. PubMed ID: 24639013
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of apoptosis in osteogenic sarcoma cells by combination of tumor necrosis factor-related apoptosis inducing ligand and chemotherapeutic agents.
    Sun J; Fu ZM; Fang CQ; Li JH
    Chin Med J (Engl); 2007 Mar; 120(5):400-4. PubMed ID: 17376311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The effect of survivin expression on the apoptosis and proliferation of hypoxic human pulmonary arterial smooth muscle cells].
    Zhang S; Liu B; Zhang B; Fan Z
    Zhonghua Jie He He Hu Xi Za Zhi; 2015 Jan; 38(1):45-9. PubMed ID: 25791656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Doxorubicin and edelfosine lipid nanoparticles are effective acting synergistically against drug-resistant osteosarcoma cancer cells.
    González-Fernández Y; Imbuluzqueta E; Zalacain M; Mollinedo F; Patiño-García A; Blanco-Prieto MJ
    Cancer Lett; 2017 Mar; 388():262-268. PubMed ID: 27998763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Folic acid decorated metal-organic frameworks loaded with doxorubicin for tumor-targeted chemotherapy of osteosarcoma.
    Xu W; Lou Y; Chen W; Kang Y
    Biomed Tech (Berl); 2020 Apr; 65(2):229-236. PubMed ID: 31605575
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long noncoding RNA expression profiles of the doxorubicin-resistant human osteosarcoma cell line MG63/DXR and its parental cell line MG63 as ascertained by microarray analysis.
    Zhu KP; Zhang CL; Shen GQ; Zhu ZS
    Int J Clin Exp Pathol; 2015; 8(8):8754-73. PubMed ID: 26464619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LncRNA FENDRR sensitizes doxorubicin-resistance of osteosarcoma cells through down-regulating ABCB1 and ABCC1.
    Kun-Peng Z; Xiao-Long M; Chun-Lin Z
    Oncotarget; 2017 Sep; 8(42):71881-71893. PubMed ID: 29069754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DOX-Vit D, a Novel Doxorubicin Delivery Approach, Inhibits Human Osteosarcoma Cell Proliferation by Inducing Apoptosis While Inhibiting Akt and mTOR Signaling Pathways.
    Maayah ZH; Zhang T; Forrest ML; Alrushaid S; Doschak MR; Davies NM; El-Kadi AOS
    Pharmaceutics; 2018 Sep; 10(3):. PubMed ID: 30181466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tangeretin-Assisted Platinum Nanoparticles Enhance the Apoptotic Properties of Doxorubicin: Combination Therapy for Osteosarcoma Treatment.
    Gurunathan S; Jeyaraj M; Kang MH; Kim JH
    Nanomaterials (Basel); 2019 Jul; 9(8):. PubMed ID: 31362420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Generation of reactive oxygen species is the primary mode of action and cause of survivin suppression by sepantronium bromide (YM155).
    Wani TH; Chowdhury G; Chakrabarty A
    RSC Med Chem; 2021 Apr; 12(4):566-578. PubMed ID: 34046628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. YM155-Adapted Cancer Cell Lines Reveal Drug-Induced Heterogeneity and Enable the Identification of Biomarker Candidates for the Acquired Resistance Setting.
    Michaelis M; Wass MN; Reddin I; Voges Y; Rothweiler F; Hehlgans S; Cinatl J; Mernberger M; Nist A; Stiewe T; Rödel F; Cinatl J
    Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32357518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multistage targeting and dual inhibiting strategies based on bioengineered tumor matrix microenvironment-mediated protein nanocages for enhancing cancer biotherapy.
    Hu F; Deng C; Zhou Y; Liu Y; Zhang T; Zhang P; Zhao Z; Miao H; Zheng W; Zhang W; Wang M; Ma X
    Bioeng Transl Med; 2022 May; 7(2):e10290. PubMed ID: 35600646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.